ALT5 Sigma (NASDAQ:ALTS) Stock Rating Lowered by Wall Street Zen

ALT5 Sigma (NASDAQ:ALTS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report issued on Saturday.

ALT5 Sigma Price Performance

Shares of ALTS opened at $5.94 on Friday. ALT5 Sigma has a 1-year low of $1.55 and a 1-year high of $10.95. The firm has a 50-day simple moving average of $7.84 and a two-hundred day simple moving average of $6.58. The company has a current ratio of 0.88, a quick ratio of 0.83 and a debt-to-equity ratio of 1.45.

Institutional Investors Weigh In On ALT5 Sigma

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of ALT5 Sigma by 27.6% in the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after purchasing an additional 42,157 shares during the period. Jane Street Group LLC purchased a new position in shares of ALT5 Sigma in the second quarter valued at approximately $380,000. Bridgeway Capital Management LLC boosted its stake in shares of ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after purchasing an additional 1,661 shares during the period. Finally, Evernest Financial Advisors LLC purchased a new position in shares of ALT5 Sigma in the second quarter valued at approximately $87,000. 6.27% of the stock is currently owned by institutional investors and hedge funds.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.